- Home
- IFRX vs MNSB Comparison
IFRX vs MNSB Comparison
Compare IFRX & MNSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- MNSB
- Stock Information
- Founded
- IFRX 2007
- MNSB 2003
- Country
- IFRX Germany
- MNSB United States
- Employees
- IFRX N/A
- MNSB N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- MNSB Major Banks
- Sector
- IFRX Health Care
- MNSB Finance
- Exchange
- IFRX Nasdaq
- MNSB Nasdaq
- Market Cap
- IFRX 117.8M
- MNSB 124.2M
- IPO Year
- IFRX 2017
- MNSB N/A
- Fundamental
- Price
- IFRX $1.15
- MNSB $16.60
- Analyst Decision
- IFRX Strong Buy
- MNSB
- Analyst Count
- IFRX 1
- MNSB 0
- Target Price
- IFRX $8.00
- MNSB N/A
- AVG Volume (30 Days)
- IFRX 623.9K
- MNSB 10.2K
- Earning Date
- IFRX 05-07-2025
- MNSB 04-21-2025
- Dividend Yield
- IFRX N/A
- MNSB 2.41%
- EPS Growth
- IFRX N/A
- MNSB N/A
- EPS
- IFRX N/A
- MNSB N/A
- Revenue
- IFRX $187,930.00
- MNSB $59,063,000.00
- Revenue This Year
- IFRX $396.02
- MNSB $18.73
- Revenue Next Year
- IFRX $155.22
- MNSB $9.60
- P/E Ratio
- IFRX N/A
- MNSB N/A
- Revenue Growth
- IFRX 177.12
- MNSB N/A
- 52 Week Low
- IFRX $1.14
- MNSB $14.97
- 52 Week High
- IFRX $2.82
- MNSB $20.88
- Technical
- Relative Strength Index (RSI)
- IFRX 24.46
- MNSB 50.87
- Support Level
- IFRX $1.76
- MNSB $16.27
- Resistance Level
- IFRX $1.34
- MNSB $16.46
- Average True Range (ATR)
- IFRX 0.14
- MNSB 0.20
- MACD
- IFRX -0.01
- MNSB 0.05
- Stochastic Oscillator
- IFRX 1.39
- MNSB 56.25
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.